As Nycomed officially becomes a wholly owned subsidiary of Takeda Pharmaceutical Company, Takeda has named Frank Morich as the new Nycomed CEO. Morich will also continue in his current position as Executive VP (EVP) of International Operations (Americas/Europe) for Takeda Pharmaceuticals International. “I look forward to bringing Takeda and Nycomed together to … [Read more...] about Frank Morich named new CEO of Nycomed as Takeda completes acquisition
Business
Manufacturer of MaxAir Autohaler purchased by dermatology-focused company
Graceway Pharmaceuticals, which manufactures the MaxAir Autohaler pirbuterol acetate MDI, one of the last remaining CFC-propelled metered dose inhalers, has agreed to sell all of its assest to Galderma, a " company focused exclusively on meeting the needs of dermatology patients and physicians." The MaxAir inhaler is scheduled for phase out two years from now, with a … [Read more...] about Manufacturer of MaxAir Autohaler purchased by dermatology-focused company
Intranasal insulin and PTH formulations for sale
Marina Biotech (formerly MDRNA/Nastech) is offering intellectual property related to intranasal formulations of rapid-acting insulin and of parathyroid hormone (PTH) for the treatment of osteoporosis for sale through ICAP Patent Brokerage. ICAP has recently handled a number of portfolios related to inhalation and nasal delivery, offering several at live auction in … [Read more...] about Intranasal insulin and PTH formulations for sale
MannKind looking to raise $370 million for continued development of Afrezza
MannKind Corporation has announced a proposed offer of senior secured discount notes, due 2017, that would yield approximately $370 million. The company says that it would use the money to complete Phase 3 clinical trials of its Afrezza inhaled insulin, to prepare for commercialization of the product, and for work on its manufacturing plant in Danbury, CT, among other … [Read more...] about MannKind looking to raise $370 million for continued development of Afrezza
TOBI Podhaler DPI launched in UK
Novartis has launched its TOBI Podhaler tobramycin dry powder inhaler in the UK. The DPI, for the treatment of P. aeruginosa infections in cystic fibrosis patients. The CF Trust responded to the launch on its website, noting "This is the first ever antibiotic pod haler and is a development the CF Trust welcomes." Read a brief article. … [Read more...] about TOBI Podhaler DPI launched in UK
Southwest Research Institute gets $4.4 million for development of intranasal cyanide antidote
The US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) has awarded a $4.4 million contract to Texas-based Southwest Research Institute (SwRI), an independent applied research and development organization, for development of an intranasal cyanide antidote. The only treatments for cyanide poisoning currently … [Read more...] about Southwest Research Institute gets $4.4 million for development of intranasal cyanide antidote
Sun Pharma says it will file IND for Starhaler in 2012
During its presentation at the 2011 Morgan Stanley Global Healthcare Conference on September 14, Sun Pharma Advanced Research Company (SPARC) provided a detailed report on the development of its Starhaler dry powder inhaler and announced that it plans to file an investigational new drug (IND) application in the US in 2012. The company, which co-developed the device … [Read more...] about Sun Pharma says it will file IND for Starhaler in 2012
Hearing in Proveris/Innova case delayed by Innova bankruptcy
Just prior to a scheduled hearing to determine sanctions in the Proveris Scientic vs. InnovaSystems case that was scheduled for September 6, 2011, InnovaSystems filed for bankruptcy, indefinitely delaying the hearing. The petition for Chapter 11 bankruptcy filed on September 2 in New Jersey lists two law firms that represented Innova in the patent infringement case as … [Read more...] about Hearing in Proveris/Innova case delayed by Innova bankruptcy
Hi-Tech Pharmacal’s fluticasone nasal spray sales more than double
First quarter sales of Hi-Tech Pharmacal's fluticasone proprionate nasal spray rose from $11,700,000 in 2010 to $26,200,000 this year, the company has announced, continuing a rapid increase in sales since the product was introduced. First quarter earnings rose 59% overall, which is mostly attributable to the increase in nasal spray sales. The fluticasone … [Read more...] about Hi-Tech Pharmacal’s fluticasone nasal spray sales more than double
Freeman Technology moves to new facility
Freeman Technology has moved to a new, larger facility in the Tewkesbury Business Park in Gloucestershire, UK. The new building includes office, laboratory, and manufacturing areas; additional space for expansion is available. Freeman has been actively working to expand its powder characterization instrument business, focusing on the FT4 Powder rheometer, which can … [Read more...] about Freeman Technology moves to new facility